life scienc diagnost tool
leaner meaner time end market
turnaround initi buy pt
initi coverag buy rate pt
last year face challeng end market
condit peer group life scienc tool compani due
compani rel higher exposur academic/govern
segment lower exposur fastest grow biopharma segment
meantim dilig work improv oper
profil om improv bp optim
product portfolio growth divestitur tuck-in
acquisit think brkr end market environ might turn
corner combin sharper focu oper disciplin
faster grow market opportun compani well-posit
re-acceler top line growth next month
furthermor still signific growth potenti top
line margin next sever year
end market continu improv brkr bsi revenu
order growth first nine month mid-singl
digit bode well seen posit order growth
europ revenu four quarter row improv
outlook north america last two quarter healthier
industri market trend overal vs last sever year
focu high growth high margin opportun
identifi six area focu repres revenu today
high revenu growth margin opportun exhibit
oper disciplin increasingli becom part cultur
sinc complet variou restructur initi
continu target bp om expans annual
om near there still meaning runway growth
potenti caveat less visibl best outlook result
valuat pt base sale ebitda
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
potenti near medium-term driver impact top line
expand percentag aftermarket revenu
almost driver includ increas focu structur servic
servic contract labscap magnet reson preclin
imag increas emphasi consum maldi biotyp
invest softwar develop unlik match
percentag level consumable/recur revenu seen among life
scienc tool compani higher compani believ
aftermarket revenu could attain futur
backlog million ultra-high field nmr system
gigahertz higher placement expect gener multi-million
dollar revenu first system place
uniqu capabl analys intrins disord protein
difficult protein character one two placement
ultra-high field nmr system could possibl second half
driver oper leverag go forward addit focus high-
growth high-margin product opportun still signific
runway implement lean initi throughout organ
manufactur function compani also earli inning
basebal analog term integr improv harmon variou
downsid risk buy rate pt includ
unabl re-acceler top line growth due end
market environ inabl leverag faster grow
slower-than-expect margin improv attribut
slower-than-expect adopt scientif capit equip within
brkr end market due macroeconom uncertainti
signific deterior demand emerg market
particularli china
increas competit across product portfolio faster-than-
price target base sale consensu
ebitda repres discount premium respect
compar peer group reflect compani signific runaway
margin improv somewhat less certainti reach industry-
averag growth top line near-term
report revenu growth
contribut
growth
growth
growth
acquisit
fx tailwind
fx headwind
fx headwind
contribut
fx headwind
headwind recent
recent strateg
time benefit
past
major profit
cash flow
gener
comp overhang
weak european order
first nine month
exhibit compani snapshotsourc compani report btigcompani descript develop scientif instrument analyt diagnost solut custom life scienc research pharmaceut biotechnolog appli market cell biolog clinic research microbiolog in-vitro diagnost nanotechnolog materi scienc research technolog platform includ magnet reson technolog mass spectrometri technolog ga liquid chromatographi tripl quadrupol mass spectrometri technolog x-ray technolog spark-opt emiss spectroscopi atom forc microscopi stylu optic metrolog technolog fluoresc optic microscopi infrar raman molecular spectroscopi technolog estimate compani provid high low temperatur superconduct materi devic headquart billerica histor perform non-gaap revenu mix ltm sept billionsrevenuerevenuegrowth y/ybiospin after-market
exhibit compani snapshot continu sourc compani report btigmanagementfrank laukien phd chairman presid ceo previous chairman analyt life scienc system associ anthoni mattacchion cfo emd millipor millipor gerber scientif price waterhous mark munch phd presid nano group cooligi juergen srega presid calid group thermofish badenwerkag gmbh board directorscynthia friend phd harvard univers marc kastner phd scienc philanthropi allianc mit richard kniss agil hewlett packard joerg laukien member region advisori council deutsch bank ag william linton lead director promega corpor supervisori board eppendorf ag gill martin phd eurofin scientif group director analyt bioventuressca john ornel richard packer asahi kasei corpor non-execut chairman zoll medic whistler corpor board member medic devic manufactur associ adeleneq perkin infin pharmaceut transformpharmaceut bain compani director biotechnolog industri organ massachusett biotechnolog council hermann requardt phd siemen ag robert rosenth phd tacon bioscienc imi intellig medic implant magellan bioscienc thermofish chairman director director galvan appli scienc market posit product portfolio increasingli focus six high-growth high margin area repres revenu today strengthen recent acquisit acceler futur growthphenom proteomicsbiopharma appliedmicrobiolog diagnosticsneurosci cell microscopynext-gen nanotech toolsafter-marketdriversnmr phenomicsmass spec proteom phenomicsghz-class nmr structur biologyrapiflexmaldi pharma-pulsemaldi drug imagernmr food-screen appli marketsmaldi biotyp global instal base system new consum product carbaivd pcr assay ir biotypernext-gen opto-genet super-resolut cell microscopyluxendolight sheet microscopi recent atom forc microscopi afm x-ray metrologyservic labscap softwareconsumablesaft spend cost cut portfolio priorit outsourc non-cor manufactur continu focu drive oper effici target bpom expans annual
fiscal year end dec million except per share cost cost revenu profit gener oper expens incom incom expens tax non-controlling tax non-controlling interest incom incom analysi non- gener margin rate margin margin growth non- total bpssell gener incom bpsep compani report btig estim
btig cover compani mention report
appendix analyst certif import disclosur
